Recovery Protein Nutrition as a Countermeasure for Anabolic Resistance Following Sleep Loss
PSL
1 other identifier
interventional
20
1 country
1
Brief Summary
The current study will determine protein nutritional status (MPS and WBPB) in response to military-relevant sleep loss, and whether an even protein nutrition distribution during recovery optimally supports MPS and WBPB. Adults (n=20) will complete a 7d sleep satiated phase (\~7-9h target/d), a 4d military-relevant sleep restriction phase (\~4h /d), and a 3d recovery phase (\~7-9h target/d) in a randomized, parallel design. During recovery, volunteers will consume 1.6 g protein/kg/d as an even (\~0.4/0.4/0.4/0.4 g/kg) or skewed (\~0.11/0.27/1.15/0.07 g/kg) distribution. Sleep will be monitored throughout the study using wrist actigraphy and diaries. During each phase, integrated daily MPS will be estimated using ingested deuterium oxide, salivary and blood sampling, and muscle biopsies, while WBPB will be estimated using ingested 15-N alanine and urine collections. At the end of each phase, metabolic testing will be used to assess the effects of sleep loss on substrate utilization and include consuming a carbohydrate beverage, serial blood draws, indirect calorimetry, and steady-state aerobic exercise. The knowledge products derived from the proposed effort will be informative to next generation ration development and support military-specific recovery nutrition guidance following operations involving sleep loss.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 4, 2023
CompletedFirst Posted
Study publicly available on registry
October 10, 2023
CompletedStudy Start
First participant enrolled
March 21, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 4, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 4, 2024
CompletedJanuary 21, 2026
January 1, 2026
8 months
October 4, 2023
January 16, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Whole-body Protein Balance
15N labeled stable isotope
24 hours
Integrated Muscle Protein Synthesis
deuterium oxide integrated stable isotope
72 hours
Study Arms (2)
Protein Nutrition Even
EXPERIMENTALVolunteers will consume 1.6 g protein/kg/d as an even (\~0.4/0.4/0.4/0.4 g/kg) distribution across breakfast, lunch, dinner, and a snack.
Protein Nutrition Skewed
ACTIVE COMPARATORVolunteers will consume 1.6 g protein/kg/d as a skewed (\~0.11/0.27/1.15/0.07 g/kg) distribution across breakfast, lunch, dinner, and a snack.
Interventions
Dietary Protein Nutrition Distribution
Eligibility Criteria
You may qualify if:
- Adults aged 18 - 39 years
- Body mass index \< 30.0 kg/m2
- Self-report weight stable for the past 2 months (± \~3 kg)
- Healthy without evidence of chronic illness, musculoskeletal injury, or diagnosed sleep disorder (i.e., insomnia) as determined by the USARIEM Office of Medical Support and Oversight (OMSO) or home duty station medical support
- Self-report participates in aerobic and/or resistance exercise, on average, ≥2 days per week for previous 6 months
- Willing to refrain from alcohol, smoking/using any nicotine product (includes e-cigarettes, vaping, chewing tobacco), caffeine, and dietary supplements during the intervention periods of the study
- Supervisor approval for federal civilian employees and non-HRV active duty military personnel
- Biological females must have normal menstrual cycles between 26-32 days in duration; 5 menstrual cycles within the past 6 months; or able to provide self-report documentation of sustained (i.e., \~ \>3 months) oral/hormonal contraceptive use which contains low-dose estrogen/progesterone to maintain continuous hormonal levels (i.e., IUD or no oral placebos)
You may not qualify if:
- Metabolic or cardiovascular abnormalities, gastrointestinal disorders (e.g., abnormal blood clotting, kidney disease, diabetes, cardiovascular disease, anemia etc.) as determined by OMSO or home duty station medical support
- History of complications with lidocaine (or similar local anesthetic)
- Present condition of substance abuse (e.g., alcoholism, anabolic steroid use etc.) as self-report or determined by OMSO or home duty station medical support
- Cumulative blood donation of greater than 550mL within 8-wk of beginning scheduled study blood collection
- Cumulative blood donation of greater than 550mL within 8-wk after completing scheduled study blood collection
- Pregnant, trying to become pregnant, and/or breastfeeding (results of urine pregnancy test prior to body composition scans and self-report for breastfeeding)
- Unwilling or unable to consume study diets or foods provided due to personal preference, dietary restrictions, and/or food allergies
- Unwilling or unable to adhere to study physical restrictions or sleep prescriptions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
US Army Research Institute of Environmental Medicine
Natick, Massachusetts, 01760, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jess A Gwin, PhD
United States Army Research Institute of Environmental Medicine
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 4, 2023
First Posted
October 10, 2023
Study Start
March 21, 2024
Primary Completion
November 4, 2024
Study Completion
November 4, 2024
Last Updated
January 21, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared.